---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-25-000029"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:01:37.511102+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BeiGene Q4 revenue jumps 78% to $1.13B; BRUKINSA sales double; guides FY25 $4.9-5.3B

## Summary
- Total revenue Q4 $1.13B (+78% YoY); full year $3.81B (+55% YoY).
- BRUKINSA global revenue Q4 $828M (+100%); full year $2.6B (+105%).
- Full year 2025 revenue guidance $4.9-$5.3B; anticipate positive GAAP operating income in 2025.
- GAAP operating loss narrowed to $79M in Q4 from $384M; achieved positive non-GAAP operating income of $79M.
- Advanced 6 NMEs in Q4 and 13 in full year; plan to change name to BeOne Medicines Ltd., ticker ONC.

## SEC filing metadata
- accession: 0001651308-25-000029
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130825000029/0001651308-25-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130825000029/bgne-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-25-000029
- JSON: https://secwatch.observer/filing/0001651308-25-000029.json
- Plain text: https://secwatch.observer/filing/0001651308-25-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.